
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
 "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

<html xmlns="http://www.w3.org/1999/xhtml" lang="en">

<head>
<meta name="google-site-verification" content="tpATPqNEN3HXiSbtqevBE9NdgbuCiN9Vmr6EP94lx6w" />
<meta name="keywords" content="OIG Online Portfolio: Drug Pricing and Reimbursement" />
<meta name="description" content="OIG Online Portfolio: Drug Pricing and Reimbursement" />
<title>OIG Online Portfolio: Drug Pricing and Reimbursement  | Reports & Publications | Office of Inspector General | U.S. Department of Health and Human Services</title>
<!--#include virtual="/layout/head.asp" -->




<link rel="stylesheet" type="text/css" href="./tabs.css" />
<script type="text/javascript" src="./stepcarousel.js">



/***********************************************
* Step Carousel Viewer script- (c) Dynamic Drive DHTML code library (www.dynamicdrive.com)
* Visit http://www.dynamicDrive.com for hundreds of DHTML scripts
* Please keep this notice intact
***********************************************/

</script>

<style type="text/css">

.stepcarousel{
position: relative; /*leave this value alone*/
overflow: scroll; /*leave this value alone*/
width: 585px; /*Width of Carousel Viewer itself*/
height: 240px; /*Height should enough to fit largest content's height*/
-webkit-box-sizing: border-box; /* set box model so container width and height value includes any padding/border defined */
-moz-box-sizing: border-box;
box-sizing: border-box;
}

.stepcarousel .belt{
position: absolute; /*leave this value alone*/
left: 0;
top: 0;
}

.stepcarousel .panel{
float: left; /*leave this value alone*/
overflow: hidden; /*clip content that go outside dimensions of holding panel DIV*/
margin: 0; /*margin around each panel*/
width: 150px; /*Width of each panel holding each content. If removed, widths should be individually defined on each content DIV then. */
}

span.paginatecircle{ /* CSS for paginate circle spans. Required */
background: white;
border: 2px solid black;
border-radius: 10px;
width: 6px;
height: 6px;
cursor: pointer;
display: inline-block;
margin-right: 4px;
}

span.paginatecircle:hover{
background: gray;
}

span.paginatecircle.selected{
background: black;
}

/* .caption {position:absolute; z-index:10; top:140px; left:0; width:125px;} */
.caption {width:125px; padding-left:4px; line-height:1.1}

.no-bg-exit {background-image:none !important;}

.acc_trigger {cursor:pointer;}

</style>



<script type="text/javascript">

stepcarousel.setup({
	galleryid: 'mygallery', //id of carousel DIV
	beltclass: 'belt', //class of inner "belt" DIV containing all the panel DIVs
	panelclass: 'panel', //class of panel DIVs each holding content
	//autostep: {enable:true, moveby:1, pause:2000},
	panelbehavior: {speed:500, wraparound:true, wrapbehavior:'slide', persist:true},
	defaultbuttons: {enable: true, moveby: 1, leftnav: ['/fraud/child-support-enforcement/images/prev.gif', -5, 80], rightnav: ['/fraud/child-support-enforcement/images/next.gif', -12, 80]},
	statusvars: ['statusA', 'statusB', 'statusC'], //register 3 variables that contain current panel (start), current panel (last), and total panels
	contenttype: ['inline'] //content setting ['inline'] or ['ajax', 'path_to_external_file']
})


</script>







<!-------------/ head closes and body opens / --->

<!--#include virtual="/layout/head-body-tags.asp" -->

<!------------/ head closes and body opens / --->


<div id="bodyContainer">
	<div id="textReset">
	<!--#include virtual="/layout/header.asp" -->
			<div id="mainBody">
			<div id="leftSideInterior">
				<div id="breadcrumbs">
					<ul>
						<li>
							<a href="/">Home</a>
						</li>
						<li>
							<a href="/reports-and-publications/index.asp">Reports &amp; Publications</a>
						</li>
					
						<li>
						  Portfolio and Other Reports
						</li>
					
					</ul>
				</div>
				<div id="leftContentInterior">



				<h1 id="port">OIG Online Portfolio: Drug Pricing and Reimbursement</h1>        
        
<p style="margin-bottom:20px;">This online portfolio pulls together the Office of Inspector General's (OIG) body of work since 2010 plus several older relevant items that relate to drug pricing and reimbursement in HHS programs. The portfolio features planned work, completed reports, industry guidance, and enforcement actions. This portfolio does not cover OIG's body of work focused on questionable or fraudulent billing for prescription drugs. This portfolio on drug pricing and reimbursement will be updated periodically.</p>    


<div id="tab-top">
<ul>
<li id="selected"><a href="./index.asp#mainBody">Overview</a></li>
<li><a href="./reports.asp#mainBody">Reports</a></li>
<li><a href="./impact.asp#mainBody">Impact</a></li>
<li><a href="./recommendations.asp#mainBody">Recommendations</a></li>
<li><a href="./enforcement.asp#mainBody">Enforcement</a></li>
<li><a href="./guidance.asp#mainBody">Industry Guidance</a></li>
</ul>
</div>



<div id="tab-container">

<h2>Overview</h2>

<div id="tab-interior">


<style type="text/css">
.panel {float:left; margin-right:8px;}
</style>


<div class="panel">
<a href="https://oig.hhs.gov/oei/reports/oei-02-16-00270.asp"><img src="./images/catastrophic.jpg" alt="A graphic of the report cover page" /></a>
<div class="caption"><p>Report: High-price Drugs Are Increasing Federal Payments for Medicare Part D Catastrophic Coverage</p></div>
</div>


<div class="panel">
<a href="/oas/map/"><img src="./images/map.jpg" alt="A graphic of a United States map" /></a>
<div class="caption"><p>States' Collection of Medicaid Rebates from Drug Manufacturers</p></div>
</div>


<div class="panel">
<a class="clean" href="/newsroom/news-releases/2015/sandoz.asp"><img src="./images/enforcement.jpg" alt="A graphic representing an enforcement" /></a>
<div class="caption"><p>Sandoz to Pay $12.64 Million in CMP Settlement with HHS OIG for Misrepresenting Drug Pricing Data to Medicare</p></div>
</div>


<div class="panel">
<a class="fancybox iframe clean" href="/fraud/docs/alertsandbulletins/2014/SAB_Copayment_Coupons.pdf"><img src="./images/bulletin.jpg" alt="A graphic of the first page of the document" /></a>
<div class="caption"><p>Special Advisory Bulletin: Pharmaceutical Manufacturer Copayment Coupons</p></div>
</div>


<div class="contentSeparator"></div>

<h3>Drug Pricing and Reimbursement</h3>

<p><a href="https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical.html">According to data</a> from the Centers for Medicare & Medicaid Services (CMS), U.S. prescription drug expenditures totaled $325 billion in 2015.  Spending through Department of Health and Human Services (HHS) programs accounted for 39 percent ($127 billion) of this total.  These HHS programs include Medicaid, Medicare Part B (largely for physician-administered drugs), and Medicare Part D (for most outpatient drugs).  HHS also administers the 340B Drug Pricing Program (340B program), which enables safety net health care providers to purchase outpatient drugs at discounted prices.</p>

<p>The Office of Inspector General (OIG) has a long history of assessing reimbursement policy for prescription drugs, including a <a href="https://oig.hhs.gov/testimony/docs/2006/60713fin.pdf">prominent role</a> in highlighting vulnerabilities in the prior reimbursement methodology for most drugs under Medicare Part B.  OIG's reports and enforcement work helped pave the way for legislative changes in the reimbursement methodology for most drugs under Medicare Part B and the resulting programmatic changes that saved the Federal Government billions of dollars. </p>
<p>Today, OIG continues its commitment to promoting economy and efficiency in HHS drug programs. OIG's portfolio on drug pricing and reimbursement focuses on the following areas:</p>




<h3>Data Integrity</h3>
<p>OIG work reviewing the accuracy of the data used in determining Federal drug reimbursement and rebate amounts as well as CMS's oversight and management of that data. For example, OIG identified that <a href="https://oig.hhs.gov/oei/reports/oei-03-08-00300.pdf">some manufacturers may improperly report brand-name drugs as generic drugs</a> and, consequently, pay lower Medicaid rebates. OIG has also looked at <a href="https://oig.hhs.gov/oei/reports/oei-03-05-00310.pdf">how manufacturers report the average sales price (ASP) data used to set Medicare Part B payment rates and at how CMS validates this data</a>.</p>



<h3>Program Compliance</h3> 
<p>OIG work examining whether drug manufacturers, State Medicaid agencies, and other entities are complying with statutory and program requirements. Examples include looking at the <a href="https://oig.hhs.gov/oas/map/">effectiveness of Medicaid's rebate-collection efforts</a> and <a href="https://oig.hhs.gov/oei/reports/oei-05-14-00430.asp">whether all parties are adhering to 340B program requirements</a>.</p>



<h3>Reimbursement Policy</h3>
<p>OIG work examining the financial impact of drug reimbursement and rebate policies on Federal spending. Examples include reviewing the <a href="https://oig.hhs.gov/oas/reports/region6/61500030.asp">potential savings from extending inflation-adjusted rebates to generic drugs</a> in HHS programs; examining the <a href="https://oig.hhs.gov/oei/reports/oei-03-12-00550.pdf">effect of "bundling" payments on costs for drugs to treat end-stage renal disease (ESRD)</a>; and comparing the impact of different payment methodologies across the Medicare, Medicaid and 340B programs. Through our <a href="https://oig.hhs.gov/oei/drug-pricing.asp">congressionally mandated work on ASPs and AMPs</a>, OIG plays a role in examining reimbursement rates for Part B drugs every quarter.</p>



<h3>Spending Trends </h3>
<p>OIG work describing how market prices impact Federal spending for prescription drugs in such diverse areas as <a href="https://oig.hhs.gov/oei/reports/oei-02-16-00290.pdf">compounded drugs</a>, brand-name drugs in Medicare Part D, and <a href="https://oig.hhs.gov/oei/reports/oei-02-16-00270.asp">Medicare Part D catastrophic coverage</a>. </p>



<h3>Incentive Alignment</h3>
<p>OIG work exploring situations in which entities involved with HHS programs may have incentives not aligned with HHS program goals, adversely affecting those programs and their beneficiaries. Examples include examinations of Medicare Part D plan sponsors' insights <a href="https://oig.hhs.gov/oei/reports/oei-02-08-00050.asp">into the services and information provided by pharmacy benefit managers (PBMs)</a> and of conflicts of interest on <a href="https://oig.hhs.gov/oei/reports/oei-05-10-00450.asp">pharmacy and therapeutics (P&T) committees</a>. </p>











<div class="contentSeparator"></div>

<p>Page last updated: <strong>February 17, 2017</strong></p>


<!-- Closing out Tab Divs -->
</div>
</div>





				</div><!-- leftContentInterior -->
			</div>	<!-- leftSideInterior ends -->
			<div id="rightSide">
				<!--#include file="./port-nav-pop.asp" -->
        
        
<div id="subNav">

<!--#include file="./pim-sidebar.asp" -->
        
<div class="subNavBottom"></div>
</div><!-- subNav ends -->
<div class="clear"></div>



				<div class="clearPadding"></div>
	
			</div><!-- rightSide ends -->
			<div class="clear"></div>
		</div><!-- mainBody ends -->
	</div><!-- textReset ends -->
</div><!-- bodyContainer ends -->
<div id="footerContainer">
	<!--#include virtual="/layout/footer-top.asp" -->
</div><!-- footerContainer ends -->
<div id="footerBottomContainer">
	<!-- #include virtual="/layout/footer-bottom.asp" -->
</div><!-- footerBottomContainer -->
</body>
</html>
